Cite
REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN ANTICOAGULATION FOR CONTINUOUS RENAL REPLACEMENT THERAPY IN CRITICALLY ILL CHILDREN.
MLA
Botan, E., et al. “Regional Citrate Versus Systemic Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Children.” Pediatric Critical Care Medicine, vol. 23, Nov. 2022, p. 1. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=162537730&authtype=sso&custid=ns315887.
APA
Botan, E., Durak, A., Gün, E., Gurbanov, A., Balaban, B., Kahveci, F., Özen, H., Uçmak, H., Gençay, A. G., & Kendirli, T. (2022). Regional Citrate Versus Systemic Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Children. Pediatric Critical Care Medicine, 23, 1.
Chicago
Botan, E., A. Durak, E. Gün, A. Gurbanov, B. Balaban, F. Kahveci, H. Özen, H. Uçmak, A. G. Gençay, and T. Kendirli. 2022. “Regional Citrate Versus Systemic Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Children.” Pediatric Critical Care Medicine 23 (November): 1. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=162537730&authtype=sso&custid=ns315887.